# Corcept Therapeutics Inc (CORT)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/corcept-therapeutics-inc/ JSON: https://steadybase.io/company/corcept-therapeutics-inc.json Checked Nov 10, 2026. Latest filing read: Nov 3, 2026.

## Company

- Legal name: CORCEPT THERAPEUTICS INC
- Ticker: CORT (Nasdaq)
- SEC CIK: 0001088856
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Redwood City, CA
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: corcept.com
- LinkedIn: https://www.linkedin.com/company/corcept-therapeutics
- Next earnings date: Feb 8, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $761.4M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 24, 2026). Source: https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/0001628280-26-011091-index.html
- Operating income: $44.8M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 24, 2026). Source: https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/0001628280-26-011091-index.html
- Net income: $99.7M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 24, 2026). Source: https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/0001628280-26-011091-index.html
- SG&A: $448.7M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 24, 2026). Source: https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/0001628280-26-011091-index.html
- Employees: 730 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/cort-20251231.htm
- Shares outstanding: 109,443,109 as of Oct 22, 2026 (10-Q filed Nov 3, 2026). Source: https://www.sec.gov/Archives/edgar/data/1088856/000162828026069501/0001628280-26-069501-index.html
- Auditor: Ernst & Young LLP, San Mateo, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/cort-20251231.htm

## Business

We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/cort-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $761.4M | $44.8M | $99.7M | $448.7M |
| Dec 31, 2024 | $675.0M | $137.0M | $141.2M | $280.3M |
| Dec 31, 2023 | $482.4M | $107.3M | $106.1M | $184.3M |
| Dec 31, 2022 | $401.9M | $112.6M | $101.4M | $152.8M |
| Dec 31, 2021 | $366.0M | $124.5M | $112.5M | $122.4M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/corcept-therapeutics-inc.json

## Officers and directors

- Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. LinkedIn: https://linkedin.com/in/joe-belanoff-b240618. Source: 8-K filed Nov 3, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort110326ex991pressrelease.htm
- Atabak Mokari, Chief Financial Officer. LinkedIn: https://www.linkedin.com/in/atabak-mokari-03454012. Source: Form 4 filed Sep 3, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000119312526382463/0001193125-26-382463-index.htm
- Roberto Wandenkolk Vieira, President, Oncology. Source: Form 4 filed Sep 18, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000119312526395837/0001193125-26-395837-index.htm
- Bill Guyer, PharmD, Corcept’s Chief Development Officer. Source: 8-K filed Nov 3, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort110326ex991pressrelease.htm
- Gary Charles Robb, Chief Business Officer. Source: Form 4 filed Sep 28, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000119312526405402/0001193125-26-405402-index.htm
- William Guyer, Chief Development Officer. Source: Form 4 filed Sep 3, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000119312526382475/0001193125-26-382475-index.htm
- Hazel Hunt, Chief Scientific Officer. LinkedIn: https://linkedin.com/in/hazel-hunt-6624198. Source: Form 4 filed Mar 3, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000119312526089012/0001193125-26-089012-index.htm
- G. Leonard Baker, Jr., director. Source: 8-K filed May 28, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000162828026038793/cort-20260521.htm
- Gregg Alton, director. Source: 8-K filed May 28, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000162828026038793/cort-20260521.htm
- Charles Robb, Named in proxy. Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000162828026025735/cort-20260417.htm
- Daniel N. Swisher, Jr., Board member (per proxy). Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000162828026025735/cort-20260417.htm
- David L. Mahoney, Board member (per proxy). Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000162828026025735/cort-20260417.htm
- Hazel Hunt, Ph.D., Named in proxy. Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000162828026025735/cort-20260417.htm
- James N. Wilson, Board member (per proxy). LinkedIn: https://linkedin.com/in/james-wilson-3750b4376. Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000162828026025735/cort-20260417.htm
- Joseph D. Lyon, Named in proxy. Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000162828026025735/cort-20260417.htm
- Joseph K. Belanoff, M.D., Board member (per proxy). Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000162828026025735/cort-20260417.htm
- Joshua M. Murray, Board member (per proxy). Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000162828026025735/cort-20260417.htm
- Kimberly Park, Board member (per proxy). Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000162828026025735/cort-20260417.htm
- Sean Maduck, President, Corcept Endocrinology. LinkedIn: https://linkedin.com/in/sean-maduck-9092bb1. Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000162828026025735/cort-20260417.htm
- William Guyer, Pharm.D., Named in proxy. Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1088856/000162828026025735/cort-20260417.htm

## Recent 8-K events

- Nov 3, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort-20261103.htm
- Sep 23, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526398561/d148256d8k.htm
- Jul 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/cort-20260729.htm
- Jun 17, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526274258/d159941d8k.htm
- Jun 3, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526254622/d103585d8k.htm
- May 28, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1088856/000162828026038793/cort-20260521.htm
- Apr 30, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1088856/000162828026028892/cort-20260430.htm
- Mar 25, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526123543/d123475d8k.htm
- Feb 24, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort-20260224.htm
- Feb 19, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526059551/d25779d8k.htm

## Insider trades (Form 4)

- Nov 2, 2026: Roberto Wandenkolk Vieira (President, Oncology) sold 8,333 shares, about $674,069. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526447899/0001193125-26-447899-index.htm
- Oct 15, 2026: James N. Wilson (Director) sold 10,000 shares, about $1.1M. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526424350/0001193125-26-424350-index.htm
- Oct 2, 2026: Roberto Wandenkolk Vieira (President, Oncology) sold 8,333 shares, about $967,448. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526414688/0001193125-26-414688-index.htm
- Oct 2, 2026: Joseph Douglas Lyon (See Remarks) sold 10,000 shares, about $1.2M. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526414684/0001193125-26-414684-index.htm
- Oct 2, 2026: Sean Maduck (See Remarks) sold 25,000 shares, about $2.9M. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526414674/0001193125-26-414674-index.htm
- Sep 16, 2026: Roberto Wandenkolk Vieira (President, Oncology) sold 296 shares, about $29,843. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526395837/0001193125-26-395837-index.htm
- Sep 15, 2026: James N. Wilson (Director) sold 10,000 shares, about $1.1M. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526393124/0001193125-26-393124-index.htm
- Sep 14, 2026: Joseph Douglas Lyon (See Remarks) sold 10,000 shares, about $1.1M. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526393125/0001193125-26-393125-index.htm
- Sep 2, 2026: Roberto Wandenkolk Vieira (President, Oncology) sold 58,333 shares, about $6.5M. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526382456/0001193125-26-382456-index.htm
- Sep 1, 2026: Sean Maduck (See Remarks) sold 25,000 shares, about $2.9M. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526382474/0001193125-26-382474-index.htm
- Aug 26, 2026: Kimberly Park (Director) sold 26,685 shares, about $3.3M. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526374607/0001193125-26-374607-index.htm
- Aug 25, 2026: Sean Maduck (See Remarks) sold 30,955 shares, about $3.9M. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526371388/0001193125-26-371388-index.htm
- Aug 18, 2026: David L. Mahoney (Director) sold 103,606 shares, about $12.3M. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526359255/0001193125-26-359255-index.htm
- Aug 17, 2026: Gary Charles Robb (Chief Business Officer) sold 10,000 shares, about $1.2M. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526355560/0001193125-26-355560-index.htm
- Aug 14, 2026: Sean Maduck (See Remarks) sold 3,664 shares, about $419,491. Source: https://www.sec.gov/Archives/edgar/data/1088856/000119312526355563/0001193125-26-355563-index.htm

## What management said

- "Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the growth of our endocrinology business" Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer (8-K filed Nov 3, 2026). Source: https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort110326ex991pressrelease.htm
- "The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome" Bill Guyer, PharmD, Corcept’s Chief Development Officer (8-K filed Nov 3, 2026). Source: https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort110326ex991pressrelease.htm

## Latest filings

- 8-K filed Nov 3, 2026: https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort-20261103.htm
- 10-K filed Feb 24, 2026: https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/cort-20251231.htm
- 10-Q filed Nov 3, 2026: https://www.sec.gov/Archives/edgar/data/1088856/000162828026069501/cort-20260930.htm
- DEF 14A filed Apr 17, 2026: https://www.sec.gov/Archives/edgar/data/1088856/000162828026025735/cort-20260417.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/